Among men with prostate cancer, diabetes status did not significantly affect 5-year overall survival, according to findings published in Endocrine Practice.
Nina J. Karlin, MD, of the division of hematology and medical oncology at Mayo Clinic Hospital, and colleagues evaluated 276 men (mean age, 72.1 years) with prostate cancer and diabetes newly diagnosed from 2007 to 2014 matched to 276 men (mean age, 72.1 years) with prostate cancer without diabetes to determine how diabetes affects short-term overall survival.
Nina J. Karlin
BMI was higher in participants with diabetes compared with those without diabetes (P = .03).
Mean HbA1c was 6.7% among participants with diabetes, and values did not change significantly over 1 year. Mean glucose values were higher among participants with diabetes compared with those without diabetes (P < .001 for group).
Diabetes status did not significantly alter overall survival. The 5-year overall survival was estimated to be 88% for participants with diabetes and 93% for participants without diabetes after a median follow-up of 43.7 months.
“[Diabetes] did no adversely impact survival in patients with prostate cancer,” Karlin told Endocrine Today. “In addition, prostate cancer and its treatment did not affect glycemic control. Providers can be reassured that the concurrent diagnoses do not adversely interact to worse short-term outcomes. Our findings should be confirmed in a larger data set and over a longer period of time.” – by Amber Cox
For more information:
Nina J. Karlin, MD,
can be reached at firstname.lastname@example.org.
Disclosure: The researchers report no relevant financial disclosures.